CHS-007-01/ RTOG Foundation Study 3521

Status Date:  April 01, 2024  | Status:  Open to Accrual

The "TRANSPARENT" Study

TRANSPARENT: Single-Arm Study of Toripalimab in Combination with Cisplatin and Gemcitabine in Recurrent Metastatic Nasopharyngeal Carcinoma Systemic Treatment Naïve Participants

Principal Investigator

Anna Spreafico, MD

Primary Objective

To evaluate the efficacy of toripalimab in combination with chemotherapy (cisplatin and gemcitabine), as measured by objective response rate (ORR) assessed by a Blinded Independent Central Review Committee (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1.

Patient Population

Patients with recurrent, metastatic nasopharyngeal cancer with either Epstein-Barr virus (EBV)-associated or non-EBV associated disease.

Participating Sites

Institution Name City State/Country
University of California, San Francisco San Francisco CA

Participate in RTOG Research

To participate as an RTOG study investigator, your organization must be part of the RTOG Foundation network. Patients who wish to participate in a study must be under the care of an RTOG participating investigator. For additional information, email info@rtog.org or call 1-215-574-3173.

See our clinical trials